D
uring more than a decade of clinical use, linezolid has demonstrated clinical effectiveness for treating infections caused by a variety of Gram-positive pathogens (1) (2) (3) (4) . The clinical data have been supported by the LEADER Surveillance Program established in 2004, which has monitored the activity, spectrum and susceptibility/resistance rates of this oxazolidinone in the United States for eight consecutive years (5, 6) . Table 1 summarizes the linezolid nonsusceptibility rates documented during the 8-year LEADER Program, which illustrates the low rates observed for the monitored species and groups of Gram-positive organisms. In this study, we report the results obtained during the ninth consecutive (2012) year of the LEADER Program by applying centralized testing by reference microdilution methods.
A total of 7,429 Gram-positive pathogens cultured in 60 U.S. medical centers (in 37 states) located in all nine U.S. Census Bureau Regions, including 7 medical centers specializing in children's health care, were submitted to JMI Laboratories (North Liberty, IA). Isolates were primarily identified by the participating laboratory, and the identifications were confirmed by the reference monitoring laboratory (JMI Laboratories) by using standard algorithms and Vitek 2 (bioMérieux, Hazelwood, MO), supported by matrix-assisted laser desorption ionization time-offlight mass spectrometry (MALDI-TOF-MS; Bruker Daltonics, Bremen, Germany).
Isolates were tested for susceptibility by broth microdilution following the methods in Clinical and Laboratory Standards Institute (CLSI) document M07-A9 (7). Testing was performed using panels manufactured by Thermo Fisher Scientific (Cleveland, OH). Isolates with initial linezolid MIC results at Ն4 g/ml were submitted to additional testing using customized frozen-form panels, molecular characterization of resistance mechanisms, and epidemiology typing, as previously described (8) (9) (10) . Bacterial inoculum density was monitored by colony counts to ensure an adequate number of cells for each testing event. Validation of the MIC values was performed by concurrent testing of CLSI-recommended quality control reference strains (Staphylococcus aureus ATCC 29213, Enterococcus faecalis ATCC 29212, and Streptococcus pneumoniae ATCC 49619) (11) . MIC interpretations were based on the CLSI document M100-S23 (2013) breakpoint criteria, as available (11) . Isolates resistant to erythromycin but susceptible to clindamycin were subjected to the CLSI broth microdilution inducible clindamycin resistance screening test (11) .
All S. aureus isolates tested (2,980) were inhibited by linezolid at Յ2 g/ml, except for two and one isolates displaying MIC values at 4 and 32 g/ml, respectively (Tables 2, 3 , and 4). The former isolates carried the cfr gene, while the latter strain had mutations in the 23S rRNA and the L3 ribosomal protein (Table 4) . Daptomycin, vancomycin, gentamicin, and trimethoprim-sulfamethoxazole demonstrated high levels of antimicrobial coverage (Ն97.0% susceptible) when tested against methicillin-resistant S. aureus (MRSA), while ciprofloxacin (66.1% resistance), erythromycin (88.4%), and clindamycin (25.4 and 12.3% constitutive and inducible resistance, respectively) showed high resistance rates (Table 3) . Nearly all (99.1%) coagulase-negative staphylococci (CoNS) were also inhibited by linezolid at Յ2 g/ml, whereas seven (0.9%) isolates displayed MIC values of 16 to 128 g/ml (Tables 2 and 4 ). Linezolid and daptomycin, followed by vancomycin, were the most potent agents tested against CoNS. Other agents had limited activities (36.5 to 85.0% susceptible) ( Table 3) .
Linezolid was equally potent when tested against both E. faecalis and E. faecium (MIC 50/90 , 1/2 g/ml for both) ( Table 2) , and linezolid-nonsusceptible enterococci showed a 23S rRNA mutation at position G2576 (Table 4 ). In addition, one E. faecium isolate from New Orleans was cfr positive, which represents the first detection of cfr in enterococci in the United States. All E. faecalis isolates except one remained susceptible to ampicillin, and totals of 73.7% (191/259) and 3.6% (23/640) of the E. faecium and E. faecalis isolates, respectively, were vancomycin resistant (data not shown). Overall, linezolid (MIC 50/90 , 1/2 g/ml) and daptomycin (MIC 50/90 , 1/2 g/ml) were equally potent when tested against the U.S. collection of enterococci, whereas other agents showed narrower antimicrobial coverage (49.1 to 77.7% susceptible) ( Table  3) . Linezolid (MIC 50/90 , 1/1 g/ml) showed uniform potency when tested against S. pneumoniae and other streptococcal groups of organisms (Tables 2 and 3) . Moreover, ceftriaxone, levofloxacin, and vancomycin had good antimicrobial coverage (Ն91.5% susceptible).
The linezolid resistance mechanisms detected among selected isolates corroborate those documented in previous LEADER reports (5, 6, (12) (13) (14) (15) , including cfr and G2576 alterations in S. aureus, multiple mutations in 23S rRNA and ribosomal proteins in CoNS, which translate into higher linezolid MIC values, and the G2576 modification in enterococci. The presence of cfr in S. aureus remains of particular importance due to the role of this species in causing community-and hospital-acquired infections and the fact that these organisms often display a linezolid MIC result at the CLSI and European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoint for susceptibility (i.e., Յ4 g/ml) (11, 16) . This may further facilitate the spread of this mobile resistance determinant, emphasizing the importance of active surveillance. Additional genetic analysis demonstrated the presence of clonally related S. epidermidis isolates in a single site in North Carolina, as well as isolates with pulsed-field gel electrophoresis (PFGE) profiles similar to those observed during previous years of the LEADER Program, suggesting persistence of resistant lineages within institutions (New Jersey and Tennessee) (see Table 4 ).
This report confirms high susceptibility rates for linezolid when tested against isolates from U.S. hospitals during 2012 and sustained rates compared with the rates in previous surveillance years ( Table 1) . The low number of isolates nonsusceptible to linezolid relates to the fact that target site modifications, which are still the main mechanism of resistance, develop slowly due to the redundancy of rRNA in bacteria (17) . The development (target site mutation) and acquisition (cfr) of resistance have been associated with linezolid exposure and/or prolonged treatment (8, 18, 19) . Moreover, selection of isolates related to persistent clones within a given institution has also been described (10, 20) . In addition, occasional outbreaks of cfr-carrying isolates, which have usually been contained after implementation of infection control measures, have recently been reported (9, 21) . Nevertheless, it remains prudent to maintain such national and/or global surveillance programs, not only for monitoring the drug activity and a Preliminary elevated or nonsusceptible MICs (Ն4 g/ml) (Thermo Fisher Scientific) were confirmed by using a customized frozen-form panel with an extended linezolid dilution range (i.e., 1 to 128 g/ml). b Pulsed-field gel electrophoresis (PFGE) types were assigned according to the organism code, comprised of the origin of the isolate (medical site number), followed by a capital letter (type) and a number (subtype), when applicable. Comparisons of PFGE profiles followed the criteria established by Tenover et al. (22 spectrum but also for detecting the development and/or acquisition of resistance, such as cfr in S. aureus and E. faecium.
